5-Amino-1MQ vs Berberine for Metabolic Health

People searching for 5-amino-1MQ often land there after reading about berberine and wanting something that sounds more targeted or mechanistic. That instinct is understandable, but it inverts the actual evidence gradient. Berberine's problems are about effect size and study quality. 5-amino-1MQ's problem is that the human evidence category is essentially empty.

What is 5-amino-1MQ, exactly?

5-amino-1-methylquinolinium (5-amino-1MQ) is a small organic molecule, not a peptide, that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-group metabolism. It has no FDA-approved use for any condition, and it is not on the FDA's 503A bulk drug substances list for compounding (FDA 503A bulk substances list). It is sold in the research-chemical and supplement gray market, which means quality control, dosing, and purity are unverified by any regulator. Background on the mechanism and the compound itself is covered in what 5-amino-1MQ is and how NNMT inhibition works.

What does berberine have that 5-amino-1MQ doesn't?

Berberine is an isoquinoline alkaloid extracted from plants such as Berberis species, sold as an oral supplement, most often marketed for blood sugar and lipid support. Unlike 5-amino-1MQ, berberine has a substantial body of human randomized trial data accumulated over roughly two decades, covering glycemic and lipid endpoints in people with metabolic syndrome or type 2 diabetes. That trial base is heterogeneous in quality, dosing, and duration, and effect sizes reported across it are modest and inconsistent between studies. This page's sourced evidence base is the NNMT and 5-amino-1MQ literature listed below; a rigorous berberine-specific evidence review with primary trial citations belongs on a dedicated berberine page and should not be summarized here with invented numbers. What matters for this comparison is structural: berberine has been tested in humans at all. 5-amino-1MQ has not.

Is the mechanism reason to expect similar effects?

No. NNMT regulates nicotinamide, 1-methylnicotinamide, and cellular methyl-donor (SAM) availability, and it is implicated in adipocyte and hepatic metabolism in preclinical models (NNMT in obesity and type 2 diabetes, NNMT at the crossroads of metabolism and epigenetics). 5-amino-1MQ was developed as a selective, membrane-permeable NNMT inhibitor and reversed diet-induced obesity in mice (selective NNMT inhibitors reverse diet-induced obesity in mice), with related inhibitor scaffolds explored across multiple medicinal chemistry programs (alkynyl bisubstrate NNMT inhibitors, tricyclic NNMT inhibitors, macrocyclic peptide allosteric NNMT inhibitors). More recent rodent work links NNMT inhibition to improved obesity-related metabolic dysfunction and to cardiac structural improvements in a heart-failure-with-preserved-ejection-fraction mouse model (NNMT inhibition and obesity-related metabolic dysfunction, NNMT inhibition in HFpEF mouse model). This is legitimate target biology, but a mouse mechanism is not a human outcome. Berberine's proposed mechanisms (AMPK activation, effects on lipid and glucose handling) are also incompletely mapped to its clinical effects, but at least the clinical effects themselves have been directly measured in people. Details on the 5-amino-1MQ mechanism and its limits are in NNMT inhibition mechanism and weight-loss evidence for 5-amino-1MQ.

Do we know how either compound behaves in the body?

For 5-amino-1MQ, the only pharmacokinetic data available are from rats, using an LC-MS/MS assay to characterize plasma levels and oral bioavailability (5-amino-1MQ rat pharmacokinetics and oral bioavailability). There is no published human pharmacokinetic, dose-response, or safety dataset. That means nobody selling 5-amino-1MQ as a supplement has human data to base a dose on, a fact discussed further in 5-amino-1MQ dosing claims and oral bioavailability. Berberine's oral bioavailability and absorption in humans have been characterized well enough that clinicians and researchers can discuss typical dosing ranges and known interactions (notably CYP3A4 and CYP2D6 effects, and additive risk with other glucose-lowering agents) without relying on animal extrapolation.

The comparison that actually matters

The asymmetry is the finding. This is not a table where one compound wins on more rows. It is a table showing that only one compound has enough data to even be evaluated on most rows.

Does an NNMT mechanism story make 5-amino-1MQ more "advanced" than berberine?

No, and this is worth saying directly because marketing for 5-amino-1MQ often implies exactly that. A more specific molecular target does not substitute for human safety and efficacy data. Statins, metformin, and GLP-1 receptor agonists all have precise mechanisms and enormous human trial programs behind them. 5-amino-1MQ has a plausible mechanism and zero human trials. Being mechanistically interesting is not the same as being clinically validated, and readers comparing it to GLP-1 therapies should see 5-amino-1MQ vs GLP-1 for how that gap looks against an actually approved drug class.

What is established, what is plausible, and what is not established

Established: NNMT is a real metabolic enzyme with documented roles in nicotinamide handling, adipocyte biology, and several disease models (NNMT as a metabolic syndrome target, NNMT: from pathways to therapeutic targets). Berberine has decades of human research behind it, however uneven in quality.

Plausible but unproven: that NNMT inhibition with 5-amino-1MQ produces meaningful metabolic benefit in humans at any safe, defined dose. Rodent data support the hypothesis; nothing supports the human translation yet.

Not established: any human dose, safety margin, drug interaction profile, or long-term outcome for 5-amino-1MQ. Also not established: that 5-amino-1MQ is superior, equivalent, or inferior to berberine in humans, because the comparison requires human 5-amino-1MQ data that does not exist.

When should this prompt a conversation with a clinician rather than a purchase decision?

Anyone already taking berberine, metformin, or other glucose-lowering agents should not add an unregulated, unstudied compound like 5-amino-1MQ without medical input, given the unknown interaction risk. Anyone considering either compound for diabetes or significant metabolic disease should discuss it with a physician rather than self-directing therapy based on supplement marketing. If a product marketed as 5-amino-1MQ causes unexpected symptoms, GI distress, unusual fatigue, or any acute reaction, stopping the product and seeking medical care is more appropriate than troubleshooting dose or timing. For a broader look at what side effect signals exist at all, see 5-amino-1MQ side effects and safety, and for how regulatory status is tracked across compounds like this, see the FDA Peptide Status Tracker and 5-amino-1MQ FDA status.

The practical takeaway is not that berberine is a strong intervention on its own. It is that berberine has cleared a bar 5-amino-1MQ has not even approached: being tested in a human being and reported in the literature.